Agenus Stock Price, News & Analysis

Agenus (Nasdaq: AGEN) appointed Dr. José Iglesias as Chief Medical Affairs Officer effective November 10, 2025 to lead global medical affairs for the BOT/BAL combination as it advances through the Phase 3 BATTMAN program.

Dr. Iglesias will oversee medical evidence generation, scientific exchange, and early-access frameworks, including France’s Autorisation d’Accès Compassionnel (AAC), where BOT/BAL has received AAC authorization with full government reimbursement and treatment has begun for eligible MSS colorectal cancer patients. Agenus plans named-patient and other early-access programs in additional geographies and emphasizes collecting robust real-world evidence.

Agenus (Nasdaq: AGEN) reported Q3 2025 results and a business update highlighting clinical and regulatory progress for botensilimab plus balstilimab (BOT/BAL).

Key items: France authorized reimbursed compassionate access for BOT/BAL in refractory MSS mCRC without active liver metastases; Phase 3 BATTMAN global registrational trial launching Q4 2025 across 100+ sites; updated survival data showing 42% two‑year OS in 123 MSS mCRC patients and 39% two‑year OS across >400 pan‑tumor patients; a ~$100.9M gain from MiNK deconsolidation and a $10M bridge ahead of an anticipated $91M Zydus closing.

Agenus (Nasdaq: AGEN) said it will release its third quarter 2025 financial results before the market opens on Monday, November 10, 2025.

The company also plans a stakeholder briefing webcast in late November to provide a corporate and clinical development update; timing and access details will be announced in the coming weeks.

Agenus (Nasdaq: AGEN) reported updated clinical data for the botensilimab (BOT) plus balstilimab (BAL) combination from expansion cohorts of the Phase 1b C-800-01 study presented at ESMO 2025. Across 411 enrolled patients (339 evaluable), the pan-tumor dataset showed a 2-year overall survival (OS) of 39%, median OS of 17.2 months, and objective response rate (ORR) of 17%. Sixty-one percent received ≥3 prior lines of therapy. The combo was generally tolerable with reversible immune-related GI events and no treatment-related deaths. France granted compassionate access for BOT+BAL in refractory MSS mCRC.

Agenus (Nasdaq: AGEN) will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025 at 4:00 p.m. ET to share post-ESMO clinical updates and global access progress for its immunotherapy combination botensilimab (BOT) and balstilimab (BAL).

Speakers include Michael S. Gordon, MD, discussing ESMO 2025 results from >400 patients treated with BOT/BAL across refractory solid tumors, and Alexander M.M. Eggermont, MD, PhD, on France’s AAC program and BOT/BAL inclusion. The session, moderated by Garo Armen, will end with live Q&A. No pre-registration is required and a webcast link is provided.

Agenus (NASDAQ: AGEN) has achieved a significant milestone as its investigational combination therapy botensilimab plus balstilimab (BOT/BAL) receives reimbursed compassionate access in France for treating refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

The treatment will be available through France's Accès compassionnel (AAC) framework, with 100% coverage by Assurance Maladie for eligible patients. Clinical data shows promising results, including ~21-month median overall survival, ~42% 2-year survival, and ~20% objective response rate in expanded cohorts.

The AAC authorization enables hospital use with full reimbursement at the invoiced purchase price, outside the Diagnosis-related Group. EU/EEA patients may access the treatment in France under specific directives, while non-EU countries like Turkey can participate through treatment-abroad programs.

Agenus (NASDAQ:AGEN), an immuno-oncology company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.

The company's executives, Dr. Richard Goldberg (Chief Development Officer) and Dr. Robin Taylor (Chief Commercial Officer), will conduct a fireside chat on September 9, 2025, from 10:00-10:30 AM EST. They will discuss the BOT/BAL immunotherapy program, including updates on the pivotal Phase 3 BATTMAN trial in metastatic colorectal cancer, clinical data, partnerships, and upcoming milestones for H2 2025.

Agenus (Nasdaq: AGEN), a leader in immuno-oncology, has announced updated details for its virtual Stakeholder Briefing scheduled for August 27, 2025, at 4:00 p.m. ET. The webcast will feature a new virtual format and updated participation link, requiring no pre-registration.

The briefing will cover several key areas including strategic and financial overview, Zydus partnership updates, colorectal cancer (CRC) studies, BOT/BAL clinical updates, and Phase 3 BATTMAN study in metastatic CRC. Additionally, the session will spotlight MiNK Therapeutics, where Agenus holds a significant stake.

Distinguished speakers include CEO Garo H. Armen, Chief Development Officer Richard M. Goldberg, and other experts in GI oncology and cancer research. The event will conclude with a live Q&A session.

Agenus (NASDAQ: AGEN), an immuno-oncology company, will host a virtual Stakeholder Briefing on August 27, 2025, at 4:00 p.m. ET. The event will feature presentations from senior management and industry experts focusing on developments in cancer treatment.

Key topics include strategic updates on the botensilimab (BOT) and balstilimab (BAL) programs, progress following the Zydus partnership, colorectal cancer (CRC) studies including the Phase 3 BATTMAN study, and future milestones. Notable speakers include CEO Garo H. Armen, MiNK Therapeutics CEO Jennifer Buell, and newly appointed Chief Development Officer Richard M. Goldberg, along with experts from Duke University and the Canadian Cancer Trials Group.